CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Strategic Collaboration Agreement • November 2nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the [•] day of October, 2020 (the “Effective Date”) by and between FUSION PHARMACEUTICALS INC., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6 (“Fusion”), and ASTRAZENECA UK LIMITED, a company incorporated in England and Wales (company number 03674842) whose registered address is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom CB2 0AA (“AstraZeneca”). AstraZeneca and Fusion each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in ARTICLE 1. All attached appendices, exhibits and schedules are a part of this Agreement.
